November 20, 2024

Topical Discussion

Video

Quick Takes: Hooman Allayee on the Lingering Risk of MACE for COVID-19 Patients

05:20

UK Biobank data suggest it makes sense to be vigilant about CV prevention even years after SARS-CoV-2. Hooman Allayee, PhD, explains why.

COVID

Hooman Allayee

quick takes

Topical Discussion

Advertisement

Latest Videos

15:29

Beyond the Data: Digesting the 2024 ESC CCS Guidelines

17:12

Ultralow-Contrast PCI: Why, What, and How?

23:49

The ARTIST Study and the Future of TAVR for Aortic Regurgitation

55:41

CathWorks FFRangio: Coronary Physiology Redefined

21:08

Hearing and Learning From Patients Undergoing AVR

08:59

Fellows Forum: Should CV Surgeons Train in Interventional?

11:34

Fellows Forum: Is It Safe to Allow Fellows Perform Complex PCI?

09:44

TCT 2024: Shark Tank Award

02:37

Next Generation TAVR Planning with DASI Simulations: Artificial Intelligence and Prediction-Based Algorithms

11:05

The Impact of Valve Flow Dynamics on Disease Regression and Outcomes After TAVR

00:20

Cerebral Embolic Protection – A Next Generation Approach for Contemporary TAVR Practice

05:20

Quick Takes: Hooman Allayee on the Lingering Risk of MACE for COVID-19 Patients

Partner Content

Explore All

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.